Cargando…

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are the primary treatments for ovarian cancer; however, patients often succumb to recurrence with chemotherapeutic resistance within several years after the initial treatment. In the past two decades, immunotherapy ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chang, Xia, Bai-Rong, Zhang, Zhao-Cong, Zhang, Yong-Jian, Lou, Ge, Jin, Wei-Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572849/ https://www.ncbi.nlm.nih.gov/pubmed/33123161 http://dx.doi.org/10.3389/fimmu.2020.577869

Ejemplares similares

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
por: Lin, Guang-Tan, et al.
Publicado: (2022)

Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
por: Wang, Yaqi, et al.
Publicado: (2022)

Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer
por: Zhou, Long, et al.
Publicado: (2023)

Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
por: Qiao, Yujin, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report
por: Cao, Xiaomeng, et al.
Publicado: (2022)

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
por: Xu, Jiawei, et al.
Publicado: (2022)

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer
por: Zhang, Zhao-Cong, et al.
Publicado: (2021)

Adjuvanted Immunotherapy Approaches for Peanut Allergy
por: Johnson-Weaver, Brandi T., et al.
Publicado: (2018)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
por: Liu, Yunsong, et al.
Publicado: (2023)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
por: Qin, Hao, et al.
Publicado: (2023)

Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer
por: Yang, Xinyi, et al.
Publicado: (2022)

Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors
por: Li, Jian, et al.
Publicado: (2023)

Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy
por: Lin, Yi, et al.
Publicado: (2022)

Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed
por: Hu, Xiaoyi, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
por: Zhu, Jiahao, et al.
Publicado: (2023)

Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis
por: Wang, Hesong, et al.
Publicado: (2023)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Corrigendum: Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential
por: Pi, Ya-Nan, et al.
Publicado: (2022)

Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential
por: Pi, Ya-Nan, et al.
Publicado: (2021)

A high interferon gamma signature of CD8(+) T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer
por: Li, Sen, et al.
Publicado: (2023)

Exosomes: A potential tool for immunotherapy of ovarian cancer
por: Gong, Xiangjin, et al.
Publicado: (2023)

Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume I
por: Di, Xiang-jie, et al.
Publicado: (2023)

An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance
por: Yang, Kai, et al.
Publicado: (2018)

Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy
por: Zhang, Er-lei
Publicado: (2023)

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
por: Xu, Hao, et al.
Publicado: (2023)

Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
por: Xie, Hongyu, et al.
Publicado: (2021)

The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy
por: Zhou, Jin, et al.
Publicado: (2022)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

Modulation of dendritic cell metabolism by an MPLA-adjuvanted allergen product for specific immunotherapy
por: Zimmermann, Jennifer, et al.
Publicado: (2022)

Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study
por: Su, Jin, et al.
Publicado: (2022)

IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines?
por: Zhao, Yue, et al.
Publicado: (2022)

Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer
por: Song, Junquan, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
por: Zhu, Jie, et al.
Publicado: (2022)

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
por: Wu, Wen-Jie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q90fgqa4gjmf121bi5vrjsa9ln